Maestro MEA Platform Powers First Stem Cell Cardiac Safety Assay in FDA ISTAND Program
February 18, 2026
ATLANTA, GA -- Axion BioSystems today announced that the FDA's Center for Drug Evaluation and Research (CDER) has accepted the company’s letter of intent (LOI) into the Innovative Science and Technology Approaches for New Drugs (ISTAND) Program for its Human iPSC-Cardiomyocyte MEA Assay for Prediction of Clinical Cardiovascular Repolarization Risk. The submission represents the first stem cell-derived, [...]
February 18, 2026
SAN DIEGO -- Singular Genomics, a company delivering high-throughput spatial technologies to advance precision medicine, today announced the commercial launch and U.S. availability of G4X. The launch marks a major milestone in making large-scale spatial multiomics accessible for translational research, spatial pathology, and AI-driven insights. The G4X platform enables simultaneous analysis of 500-plex RNA, 18-plex protein and fH&E [...]
New Pricing for epMotion 5073 to Enhance Liquid Handling Automation Accessibility
February 18, 2026
Eppendorf, a leading life sciences company, is excited to announce a substantial new price point for its popular epMotion 5073 automated liquid handling system. This change reflects Eppendorf’s commitment to making liquid handling automation more attainable for all laboratories, supporting greater efficiency and consistency in everyday lab workflows without compromising on Eppendorf’s known superior quality [...]
February 18, 2026
Industry-first probes featuring computationally designed binding proteins provide unprecedented affinity, baseline stability, and data quality for antibody characterization and biologics research PALO ALTO, CA & Seattle, WA — Gator Bio, a pioneer in biolayer interferometry (BLI) technologies, today announced the commercial launch of its Gator HIS XT probes, the first biolayer interferometry probes to incorporate AI-designed binding [...]
February 18, 2026
MARCY-L'ÉTOILE, France -- bioMérieux, a world leader in the field of in vitro diagnostics, today announces the launch of SMARTBIOME™, an innovative solution designed to help food manufacturers better understand, control and prevent microbiological spoilage. By combining high‑precision DNA sequencing, advanced bioinformatics and bioMérieux's microbiology expertise, SMARTBIOME™ provides actionable insights to protect product quality, reduce waste and better preserve [...]
February 18, 2026
New SciSure and Safety Partners partnership connects consulting EHS expertise with a unified digital lab platform to simplify compliance and enhance lab safety. SciSure, the Scientific Management Platform that unifies research operations, inventory, and EHS for research labs, today announced a strategic partnership with Safety Partners, part of Trinity Consultants Life Sciences and a leading [...]
February 17, 2026
3RnD® platform connects targets, compounds and authenticated human cell models to reduce manual searching and enable earlier, more informed R&D decisions By combining Cytion’s authenticated cell models with 3RnD’s data and AI workflow, we enable earlier, more reproducible and more actionable safety insight” — Jonathan Steubing, CEO, Cytion HEIDELBERG, BADEN-WüRTTEMBERG, GERMANY — Cytion, a trusted provider of [...]
February 17, 2026
BOULDER, Colo. -- Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, for certain foundational CRISPR-Cas9 intellectual property for use in NGS library preparation. While CRISPR-Cas9 technologies are most commonly associated with their unique ability to find [...]
February 17, 2026
Delivers up to 2× higher sensitivity than stainless steel microflow columns, lowering detection and quantitation limits across high-throughput bioseparations, DMPK, and 'omics applications.1 Uses up to 75% less sample than 2.1 mm I.D. columns, conserving precious materials such as cell and gene therapy and personalized medicine candidates while delivering deeper insights. 2 Reduces solvent consumption by up to [...]
Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement
February 17, 2026
B-Body® platform complements Twist’s antibody discovery offering enabling rapid, efficient and precise expression and discovery of complex bispecific antibody therapeutics Platform to power high-throughput characterization of bispecific antibodies to fuel AI-enabled and traditional drug discovery SOUTH SAN FRANCISCO, Calif. -- Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has [...]

